(Q38126803)

29 August 2017

title

Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension (English)

1 reference

29 August 2017

main subject

cardiovascular disease

1 reference

Steven G Chrysant

1

1 reference

29 August 2017

publication date

1 October 2013

1 reference

Current Hypertension Reports

29 August 2017

published in

1 reference

29 August 2017

volume

15

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

475-483

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-013-0377-9

29 August 2017

exact match

0 references

cites work

Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5).

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Identification of human PDE7B, a cAMP-specific phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Cardiovascular data on sildenafil citrate: introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Sildenafil for male erectile dysfunction: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Global and regional causes of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-I expression and cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Cardiac uses of phosphodiesterase-5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Hypertension, antihypertensive therapy, and erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Effects of antihypertensive therapy on sexual activity in hypertensive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Cardiovascular effects of tadalafil in patients on common antihypertensive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Effect of sildenafil on cardiac performance in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Mitochondria as a therapeutic target in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Animal mitochondrial biogenesis and function: a regulatory cross-talk between two genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Nitric oxide and mitochondrial biogenesis: a key to long-term regulation of cellular metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Nitric oxide and mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Effects of type 5-phosphodiesterase inhibition on energy metabolism and mitochondrial biogenesis in human adipose tissue ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Diagnosis and assessment of pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Cardiovascular effects of phosphodiesterase type 5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Daily use of sildenafil improves endothelial function in men with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Prevalence of symptoms of Raynaud's phenomenon in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Clinical practice. Raynaud's Phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Phosphodiesterase type 5 inhibitor sildenafil citrate does not potentiate the vasodilative properties of nebivolol in rat aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-013-0377-9

Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression

21 January 2018

1 reference

12 December 2020

Erectile dysfunction and subsequent cardiovascular disease

1 reference

12 December 2020

Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro

1 reference

12 December 2020

Hemodynamic effects of sildenafil in men with severe coronary artery disease

1 reference

12 December 2020

Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses

1 reference

12 December 2020

Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication

1 reference

12 December 2020

Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Tadalafil therapy for pulmonary arterial hypertension.

1 reference

12 December 2020

Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes

1 reference

12 December 2020

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy

1 reference

12 December 2020

Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

The molecular biology of cyclic nucleotide phosphodiesterases.

1 reference

12 December 2020

Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study

1 reference

12 December 2020

10.1007/S11906-013-0377-9

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1007780974

0 references

1 reference